Document is current

Article History

Received: 18 November 2024

Accepted: 2 February 2025

First Online: 14 February 2025

Declarations

:

: This study was reviewed and approved by the institutional review board of the Dana-Farber Cancer Institute, Boston, MA, USA (Clinicaltrials.gov: NCT04290546). The study was performed in compliance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from participants before inclusion in the study. Patients provided written informed consent to participate and to publish under an IRB-approved protocol at the Dana-Farber Cancer Institute where all protocol procedures were performed and data were collected.

: The funding source had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit the results.

: RD has received research funding from Ligue Contre le Cancer, Arthur Sachs, Monahan Foundation, Servier Foundation, Philippe Foundation, DCP AP-HP, honoraria from Novartis and Takeda, as well as non-financial support from Kite Pharma / Gilead and Sanofi. MSF receives funding from Calico Life Sciences, Bristol-Myers Squibb, Istari Oncology and served as a consultant for Galvanize Therapeutics. ND and AK are employees of CareDx. JK reports research support from Amgen, Equillium, BMS, Miltenyi Biotec, Regeneron, and Clinigen and consulting income from Amgen, Equillium, and Moderna Therapeutics, and is a scientific advisory board member for Cugene and Therakos. SN reports ad hoc advisory boards for Kite/Gilead, GlaxoSmith Kline, Iovance, A2 Bio and Sobi. JR receives research funding from Kite/Gilead, Novartis and Oncternal Therapuetics and serves in a consulting/advisory role for Garuda Therapeutics, LifeVault Bio, Smart Immune and TriArm Therapeutics. CJW holds equity in BionTech, Inc; and receives research funding from Pharmacyclics. She is a member of the scientific advisory boards of Adventris, Aethon Therapeutics and Repertoire. RJS serves on the board of directors for Be The Match/National Marrow Donor Program; provided consulting for Vor Biopharma, Neovii, CSL Behring, Bluesphere Bio, Cugene, Jasper, Smart Immune; and is on the Data Safety Monitoring board for Juno Therapeutics. GJH receives grant funding to institution from: ACCRF, Actuate, Bicara, BMS, Coherus, Elevar, Gateway for Cancer Research, Genentech, ImmunityBio, KSQ, Kura Oncology, Regeneron, Remix, Replimune, and Secura Bio; and serves in a consulting/advisory role to: Bicara, Coherus, Inhibrx, Kura Oncology, Merck, Naveris, Nextech, OncoSwitch, Regeneron, and Replimune. RR receives funding from CRISPR Therapeutics, Skyline Therapeutics, and is on the advisory board of Glycostem.